Medincell SA (MEDCL) - Total Assets
Based on the latest financial reports, Medincell SA (MEDCL) holds total assets worth €74.58 Million EUR (≈ $87.19 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Medincell SA (MEDCL) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Medincell SA - Total Assets Trend (2016–2025)
This chart illustrates how Medincell SA's total assets have evolved over time, based on quarterly financial data. Explore Medincell SA strategic investment ratio to see how much of total assets are deployed in long-term investments.
Medincell SA - Asset Composition Analysis
Current Asset Composition (March 2025)
Medincell SA's total assets of €74.58 Million consist of 89.1% current assets and 10.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €40.94 Million | 65.3% |
| Accounts Receivable | €3.21 Million | 3.5% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €5.27 Million | 5.8% |
| Intangible Assets | €2.65 Million | 2.9% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Medincell SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Medincell SA stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medincell SA's current assets represent 89.1% of total assets in 2025, an increase from 63.7% in 2016.
- Cash Position: Cash and equivalents constituted 65.3% of total assets in 2025, up from 5.7% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 11.0% in 2016.
- Asset Diversification: The largest asset category is cash and equivalents at 65.3% of total assets.
Medincell SA Competitors by Total Assets
Key competitors of Medincell SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €8.68 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩703.48 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
|
USA | $452.70 Million |
|
Tourmaline Bio Inc.
NASDAQ:TRML
|
USA | $269.30 Million |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230
|
China | CN¥1.32 Billion |
Medincell SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.88 | 1.46 | 3.85 |
| Quick Ratio | 2.88 | 1.46 | 3.67 |
| Cash Ratio | 0.00 | 0.50 | 0.35 |
| Working Capital | €40.02 Million | €15.10 Million | €24.21 Million |
Medincell SA - Advanced Valuation Insights
This section examines the relationship between Medincell SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 27.59 |
| Latest Market Cap to Assets Ratio | 10.41 |
| Asset Growth Rate (YoY) | 144.8% |
| Total Assets | €90.45 Million |
| Market Capitalization | $941.48 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Medincell SA's assets at a significant premium (10.41x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Medincell SA's assets grew by 144.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Medincell SA (2016–2025)
The table below shows the annual total assets of Medincell SA from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | €90.45 Million ≈ $105.75 Million |
+144.81% |
| 2024-03-31 | €36.95 Million ≈ $43.20 Million |
+25.93% |
| 2023-03-31 | €29.34 Million ≈ $34.30 Million |
-33.78% |
| 2022-03-31 | €44.30 Million ≈ $51.79 Million |
-30.35% |
| 2021-03-31 | €63.61 Million ≈ $74.36 Million |
+132.93% |
| 2020-03-31 | €27.31 Million ≈ $31.92 Million |
-28.11% |
| 2019-03-31 | €37.98 Million ≈ $44.40 Million |
+49.81% |
| 2018-03-31 | €25.35 Million ≈ $29.64 Million |
+8.97% |
| 2017-03-31 | €23.27 Million ≈ $27.20 Million |
+108.24% |
| 2016-03-31 | €11.17 Million ≈ $13.06 Million |
-- |
About Medincell SA
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder. It is also developing mdc-TJK, a subcutaneous injection that is… Read more